---
id: quanthealth
name: QuantHealth
website: quanthealth.ai
founded: 2019
area: digital twins
funding_stage: series-a
total_funding_usd_m: 30
public: false
business_model: saas
buyer:
  - pharma
  - biotech
  - investor
buyer_urgency: high
buyer_wtp: high
sales_cycle: long
regulatory_burden: heavy
tam_usd_m: 66300
last_verified: "2026-06-21"
data_centrality: core-moat
data_ownership:
  - licensed
  - public
moat:
  - data
  - model
  - IP
input:
  - real-world patient records (350M lives, 10K+ data points/patient, 10-year longitudinal)
  - biomedical knowledge graph (5M+ datapoints, 30+ sources)
  - clinical trial results database (180K trials)
  - drug database (100K drugs)
  - investigational drug target and structure data
transformation_type: predict
output:
  - virtual trial results (KM curves, PFS/OS endpoints) mirroring real trial report format
  - protocol optimization recommendations
  - indication selection guidance
  - enrollment predictions
  - market forecasting
  - probability of success scores
barrier_to_entry: very-high
barrier_to_entry_logic: 350M patient records, 5M-datapoint knowledge graph, and 180K trial database took years to license and assemble; Sanofi Ventures backing provides pharma credibility.
hardness: very-hard
hardness_reason: Producing trial simulations accurate enough that pharma sponsors trust them for go/no-go decisions with hundreds of millions at stake per program.
---

## One-liner

Trial simulation platform that predicts patient response to drugs; currently models PFS.

## Problem

Pharma sponsors lack early confidence on trial outcomes before committing to costly Phase 2/3 investment.

## Workaround

Historical base rates, expert opinion, phase transition models, CRO feasibility assessments.

## Entry wedge

Protocol optimization for oncology trials: QuantHealth entered by offering sponsors a way to virtually test protocol designs before locking them in. The first wedge was KM-curve simulation for progression-free survival in oncology, where the cost of a wrong protocol decision is highest and sponsors have the most budget.

## Method

Combines a proprietary biomedical knowledge graph (5M+ datapoints mapping drug → target → pathway → disease) with a 350M-patient real-world database to decompose individual patient journeys and digitally recompose them with any treatment, then runs virtual trials across user-defined inclusion/exclusion populations. (Source: quanthealth.ai/technology)

## TAM logic

QuantHealth positions against the total cost of late-stage trial failure. Phase 3 failures cost $800M–$1.4B per program; the global clinical trial market is ~$66B. Even modest improvement in PTS rates at Phase 2/3 represents billions in recoverable value. (Source: quanthealth.ai, paraphrased)

## Validated by

Sanofi Ventures is among the investors listed on the website (quanthealth.ai). Published case studies across ARDS, MASH, HNSCC, and IBD demonstrating platform output fidelity against real trial results. ISO 27001, SOC 2 Type 2 certified.

## Competes with

Unlearn (digital twins), inClinico/HINT (metadata prediction)

## Complements

CROs (ICON, Covance, PRA), EDC platforms (Medidata), statistical analysis vendors, competitive intelligence platforms (Citeline, Evaluate Pharma).

## Value chain position

**Downstream of:** Drug development programs
**Upstream of:** Trial execution, go/no-go decisions

## Gaps

Appears to model primarily PFS and standard efficacy endpoints; safety simulation is not described on the website. Does not use wearable or biomarker signals as inputs — relies on historical RWD, not latent biological state. Commercial model (4-fold: clinical dev, BD, portfolio strategy, competitive positioning) is the closest reference point to EF thesis.

## Notes

Most direct commercial reference point for EF thesis. Offices in Worcester MA and Tel Aviv. Partners include Sanofi Ventures among supporters shown on homepage (logos not all labeled by name).
